Aspira Women’s Health Announces Publication of Data Demonstrating Performance of its In-Development Blood Test for the Assessment of Malignancy Risk in Patients with an Adnexal Mass
September 10, 2024 08:00 ET
|
Aspira Women's Health Inc.
AUSTIN, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease...
Aspira Women’s Health to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 06, 2024 08:00 ET
|
Aspira Women's Health Inc.
AUSTIN, Texas, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease...
Aspira Women’s Health Selected as a Spoke for the Investor Catalyst Hub
September 05, 2024 08:00 ET
|
Aspira Women's Health Inc.
AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease...
Aspira Women’s Health Partners with Dorsata to Create New Clinical Workflow Tool for Adnexal Masses
August 27, 2024 08:00 ET
|
Aspira Women's Health Inc.
AUSTIN, Texas, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease...
Aspira Women’s Health Reports Second Quarter 2024 Financial Results
August 12, 2024 16:05 ET
|
Aspira Women's Health Inc.
Q2 2024 OvaSuiteSM revenue of $2.4 million and volume of 6,471 units Q2 2024 cash utilization decreased by 16% compared to Q1 2024 Full year 2024 cash guidance decreased to $13-$14.5 million ...
Aspira Women’s Health’s Announces a Poster Presentation at the 27th Annual National Association of Nurse Practitioners in Women’s Health (NPWH) Women’s Healthcare Conference
August 05, 2024 08:37 ET
|
Aspira Women's Health Inc.
AUSTIN, Texas, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease...
Aspira Women’s Health Announces Poster Presentation at the Menopause Society’s 2024 Annual Meeting
August 01, 2024 08:00 ET
|
Aspira Women's Health Inc.
AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease...
Aspira Women’s Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 12
July 31, 2024 16:05 ET
|
Aspira Women's Health Inc.
AUSTIN, Texas, July 31, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of...
Aspira Women’s Health Appoints Mr. John Ragard to its Board of Directors
July 29, 2024 09:00 ET
|
Aspira Women's Health Inc.
AUSTIN, Texas, July 29, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease...
Aspira Women’s Health Announces Preliminary Second Quarter 2024 OvaSuite Product Volume and Highlights
July 11, 2024 08:00 ET
|
Aspira Women's Health Inc.
Preliminary OvaWatch® volume during Q2 2024 grew 24% over the prior quarter to 1,307 units Preliminary OvaSuiteSM volume during Q2 2024 grew 11% over the prior quarter to 6,471 units AUSTIN, Texas,...